Your browser doesn't support javascript.
Moderately hyperglycemia as an independent prognostic factor for the worse outcome of COVID-19.
Nateghi, Saeed; Gomari, Mohammad Mahmoudi; Roudsari, Yousef Jalali; Foroughi, Alireza; Mansouri, Fariba; Shiva, Ashkan; Nasrollahizadeh, Ali; Nasiri, Zohreh; Faraji, Neda.
  • Nateghi S; Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Gomari MM; Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Roudsari YJ; Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Foroughi A; Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Mansouri F; Respiratory Department, School of Medicine, Tehran University of Medical Science, Tehran, Iran.
  • Shiva A; Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Nasrollahizadeh A; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Nasiri Z; Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Faraji N; Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: nedafaraji1368@gmail.com.
Prim Care Diabetes ; 16(3): 361-364, 2022 06.
Article in English | MEDLINE | ID: covidwho-1730024
ABSTRACT

BACKGROUND:

Blood sugar (BS) has been proposed as a prognostic factor for COVID-19. In this historical cohort study we evaluated the association between admission time BS and COVID-19 outcome.

METHODS:

First, hospitalized COVID-19 patients were divided into three groups; Non-diabetic patients with BS < 140 mg/dl (N = 394), non-diabetic patients with BS ≥ 140 mg/dl (N = 113) and diabetic patients (N = 315). Mortality, ICU admission, and length of hospital stay were compared between groups and odds ratio was adjusted using logistic regression.

RESULTS:

After adjustment with pre-existing conditions and drugs, it was shown that non-diabetic patients with BS ≥ 140 mg/dl are at increased risk of mortality (aOR 1.89 (0.99-3.57)) and ICU admission (aOR 2.62 (1.49-4.59)) even more than diabetic patients (aOR 1.72 (1.07-2.78) for mortality and aOR 2.28 (1.47-3.54) for ICU admission.

CONCLUSIONS:

Admission time hyperglycemia predicts worse outcome of COVID-19 and BS ≥ 140 mg/dl is associated with a markedly increase in ICU admission and mortality.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus / COVID-19 / Hyperglycemia Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Prim Care Diabetes Journal subject: Endocrinology Year: 2022 Document Type: Article Affiliation country: J.pcd.2022.03.005

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus / COVID-19 / Hyperglycemia Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Prim Care Diabetes Journal subject: Endocrinology Year: 2022 Document Type: Article Affiliation country: J.pcd.2022.03.005